Read the following passage and mark the letter A, B, C or D on your answer sheet to indicate the option that best fits each of the numbered...

Read the following passage and mark the letter A, B, C or D on your answer sheet to indicate the option that best fits each of the numbered blanks from 31 to 40.

A dementia diagnosis has long connoted a devastating prognosis, heralding an inexorable decline. It remains the UK’s primary cause of mortality, and its societal repercussions are projected to escalate precipitously. [I] A 2024 report commissioned by Alzheimer’s Society posited that one in three people born in the UK today will develop dementia, with case numbers anticipated to reach 1.4 million by 2040. The condition poses an enormous challenge, uniquely spanning both the health and social care systems.

For decades, substantive progress in combating the disease was agonizingly slow. Now, that landscape is undergoing a paradigm shift. For the first time, novel therapeutics have emerged that can demonstrably impede the pathology of Alzheimer’s disease, which comprises 60% of all dementia cases. [II] These new amyloid-targeting drugs—the culmination of research funded decades ago—are not a cure, but they signify a pivotal step. A robust pipeline of 138 other drugs is currently in clinical trials, targeting diverse pathways including tau proteins and inflammation.

In parallel with the biomedical quest for treatments, technological innovations are already augmenting the quality of life for those currently living with the condition. Alzheimer’s Society has collaborated with innovators like ReCuro VR, which engineered a lightweight, dementia-friendly headset. The technology is utilized in care homes to immerse patients in evocative past environments, such as a childhood home or a cherished holiday location. [III] The therapeutic outcomes have been profound; patients who had been nonverbal for months have reportedly begun speaking again, recounting their memories.

The efficacy of new drugs, however, is contingent upon a major challenge: early and accurate diagnosis. Currently, confirmation of the type of dementia (a step crucial for targeted treatments) is dependent on specialized scans that 98% of patients do not receive. [IV] The most anticipated breakthrough to rectify this deficit is the advent of simple blood tests. Alzheimer’s Society is funding a major initiative to validate and integrate these tests into the healthcare system. Such diagnostics would offer a cheap, noninvasive, and precise method to identify patients who need further support or are eligible for new treatments.

While a true cure remains a distant prospect, experts believe this convergence of new treatments, better diagnosis, and advanced AI could reclassify dementia—transforming it from a terminal diagnosis into a chronic, manageable condition, much like HIV. Early diagnosis empowers patients to plan their future care, potentially obviating the need for crisis-level medical interventions. As one neurologist noted, AI has the potential to accelerate progress "faster than I can imagine," portending a future where a dementia diagnosis is no longer regarded as an unequivocal death sentence.

Question 31: According to paragraph 1, the 2024 report on dementia's future societal impact forecasted ________.
A. a specific case number forecast of 1.4 million young people in the year 2040
B. its current status as the primary and inexorable cause of UK mortality
C. a prevalence affecting a significant fraction of the current newborn population
D. its unique impact spanning both the national health and social care systems